Document Type : Original Article

Authors

1 Faculty of Allied Health Sciences, Departent of Medical Laboratory Sciences, Health Science Center, Kuwait University, Kuwait

2 Southern Technical University College of Heaith and Medica

Abstract

Lung cancer is the leading cause of cancer death in men and the second leading cause of cancer death in women worldwide. FGFR is involved in a variety of cellular processes including angiogenesis, wound healing, tissue repair, and tumorigenesis. Recently, a common polymorphism in the transmembrane domain of the FGFR4 gene, Gly388Arg, has been reported to correlate with alteration of cell migration in vitro and with disease progression and/or survival in breast, colon, prostate and lung cancer. To evaluate the prognostic significance of the FGFR4 Gly388Arg polymorphism in lung cancer, we analyzed a case-control study of 110 lung cancer patients and 90 healthy control. Genomic DNA from whole-blood specimens was extracted using Salting-out method. Quality of DNA was evaluated by electrophoresis. To determine the distribution of FGFR4 Arg388 and FGFR4 Gly388 alleles in lung carcinoma patients, RFLP-PCR was used. In this study demonstrated that there was no relationship between polymorphism of FGFR4 Gly388Arg gene and lung cancer. Also, no significant relationship was observed between this polymorphism and clinical and pathological features of patients. It is suggested that the large casecontrol studies are needed to detect genetic determinants affecting patients’ prognosis, with the promise of targeting these putative genetic determinants to provide new therapeutic tools for patients with lung cancer.

Keywords

1.Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors,
their receptors and signaling. Endocr Relat Cancer 2000;7:165–
97.
2.Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4
function cooperatively to direct alveogenesis in the murine lung.
Development 1998;125:3615–23.
3.Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M,
Knyazeva T, Muller S, Gartner S, Sures I, Wang H, Imyanitov E,
et al. Cancer progression and tumor cell motility are associated
with the FGFR4 Arg(388) allele. Cancer Res 2002;62:840–7.
4.Wang J, Stockton DW, Ittmann M. The fibroblast growth factor
receptor-4 Arg388 allele is associated with prostate cancer
initiation andprogression. Clin Cancer Res 2004;10:6169–78.
5.Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino
U, Dragani TA. Functional FGFR4 Gly388Arg polymorphism
predicts prognosis in lung adenocarcinoma patients. J Clin Oncol
2005;23:7307–11.
6.Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M,
Signoroni S, Agresti R, Giovanazzi R, Pilotti S, Bertario L,
Ravagnani F, Dragani TA. FGFR4 Gly388Arg polymorphism
and prognosis of breast and colorectal cancer. Oncol Rep
2005;14:415–19.
7.Jezequel P, Campion L, Joalland MP, Millour M, Dravet F, Classe
JM, Delecroix V, Deporte R, Fumoleau P, Ricolleau G. G388R
mutation of the FGFR4 gene is not relevant to breast cancer
prognosis. Br J Cancer 2004;90:189–93.
8.Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen
T, Houlston RS. Further observations on the relationship
between the FGFR4 Gly388Arg polymorphism and lung cancer
prognosis. Br J Cancer 2007;96:1904–7.
9.Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev
2005;16:139–49.
10.Colvin JS, White AC, Pratt SJ, Ornitz DM. Lung hypoplasia and
neonatal death in Fgf9-null mice identify this gene as an essential
regulator of lung mesenchyme. Development 2001;128:2095–
106.
11.Usui H, Shibayama M, Ohbayashi N, Konishi M, Takada S, Itoh
N. Fgf18 is required for embryonic lung alveolar development.
Biochem Biophys Res Commun 2004;322:887–92.
12.Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A, Foster
J, Liang J, Brush J, Gu Q, Hillan K, Goddard A, et al. FGF-
19, a novel fibroblast growth factor with unique specificity for
FGFR4. Cytokine 1999;11:729–35. FIGURE 5 – Quantitation of
FGFR4, FGF9 and FGF18 gene expression
in paired normal lung (n 5 19; open boxes) and lung ADCA (n
5 19; gray-filled boxes) tissue. Data are given as in Figure 4. For all
three genes, differences between normal and tumor tissue were
statistically significant at p < 1027. 2884 FALVELLA ET AL.
13.Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland
LB, Canzian F, Haugen A. A comprehensive analysis of phase I
and phase II metabolism gene polymorphisms and risk of non-
small cell lung cancer in smokers. Carcinogenesis 2008;29:1164–
9.
14.Weir BS. Genetic data analysis 2: methods for discrete population
genetic data. Sunderlands: Sinauer Associates, Inc., 1996.
15.McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J,
Ioannidis JP, Hirschhorn JN. Genome-wide association studies
for complex traits: consensus, uncertainty and challenges. Nat
Rev Genet 2008;9:356–69.
16.Gianni-Barrera R, Gariboldi M, De Cecco L, Manenti G, Dragani
TA. Specific gene expression profiles distinguish among
functional allelic variants of the mouse Pthlh gene in transfected
human cancer cells. Oncogene 2006;25:4501–4.
17.Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN,
Gnanapragasam
VJ. Selective over-expression of fibroblast growth factor receptors 1
and 4 in clinical prostate cancer. J Pathol 2007;213:82–90.
18.Stadler CR, Knyazev P, Bange J, Ullrich A. FGFR4 GLY388
isotype suppresses motility of MDA-MB-231 breast cancer cells
by EDG-2 gene repression. Cell Signal 2006;18:783–94.
19.Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis
facilitated by developmental pathways: Sonic hedgehog, Notch,
and bone morphogenic proteins. J Cell Biochem 2007;102:829–
39.
20.Thiebault K, Mazelin L, Pays L, Llambi F, Joly MO, Scoazec
JY, Saurin JC, Romeo G, Mehlen P. The netrin-1 receptors
UNC5H are putative tumor suppressors controlling cell death
commitment. Proc Natl Acad Sci USA 2003;100:4173–8
21.Yang, Y.; Zhou, Y.; Lu, M.; An, Y.; Li, R.; Chen, Y.; Lu, D.-R.; Jin,
L.; Zhou,W.-P.; Qian, J.; et al. Associationmbetween fibroblast
growth factor receptor 4 polymorphisms and risk of hepatocellular
carcinoma. Mol. Carcinog. 2012, 51, 515–521.
22.Chen, T.H.; Yang, S.F.; Liu, Y.F.; Lin, W.L.; Han, C.P.; Wang,
P.H. Association of fibroblast growth factorreceptor 4 genetic
polymorphisms with the development of uterine cervical cancer
and patient prognosis. Reprod. Sci. 2018, 25, 86–93.
23.Tsay, M.D.; Hsieh, M.J.; Lee, C.Y.; Wang, S.S.; Chen, C.S.; Hung,
S.C.; Lin, C.Y.; Yang, S.F. Involvement of FGFR4 gene variants
on the clinicopathological severity in urothelial cell carcinoma.
Int. J. Environ. Res. Public Health 2019, 17.
24.Tateno, T.; Asa, S.L.; Zheng, L.; Mayr, T.; Ullrich, A.; Ezzat, S.
The FGFR4-g388r polymorphism promotes mitochondrial stat3
serine phosphorylation to facilitate pituitary growth hormone
cell tumorigenesis. PLoS Genet. 2011, 7, e1002400.
25.Ezzat, S.;Wang, R.; Pintilie, M.; Asa, S.L. FGFR4 polymorphic
alleles modulate mitochondrial respiration: A novel target for
somatostatin analog action in pituitary tumors. Oncotarget 2017,
8, 3481 3494.
26.Morimoto, Y.; Ozaki, T.; Ouchida, M.; Umehara, N.; Ohata,
N.; Yoshida, A.; Shimizu, K.; Inoue, H. Single nucleotide
polymorphism in fibroblast growth factor receptor 4 at codon 388
is associated with prognosis in high-grade soft tissue sarcoma.
Cancer 2003, 98, 2245–2250.
27.Dutra, R.L.; de Carvalho, M.B.; Dos Santos, M.; Mercante, A.M.;
Gazito, D.; de Cicco, R.; Group, G.; Tajara, E.H.; Louro, I.D.; da
Silva, A.M. FGFR4 profile as a prognostic marker in squamous
cell carcinoma of the mouth and oropharynx. PLoS ONE 2012,
7, e50747.
28.Choi, K.Y.; Rho, Y.S.; Kwon, K.H.; Chung, E.J.; Kim, J.H.;
Park, I.S.; Lee, D.J. ECRG1 and FGFR4 single nucleotide
polymorphism as predictive factors for nodal metastasis in oral
squamous cell carcinoma. Cancer Biomark 2012, 12, 115–124.